(TheNewswire)
7 January 2025 – TheNewswire - Edmonton, Alberta, - Innovotech Inc. (TSX-V: IOT) (“Innovotech” or the “Company”) is pleased to report that its invention for the use of antimicrobial silver compounds, including InnovoSIL™-1 silver, in a variety of formulations, was issued as European Patent No. 3 804 521 on January 1, 2025.
The patent includes claims for medical devices with Innovotech’s active silver compounds coated onto or incorporated into them, focusing on inclusion of the InnovoSIL™-1 silver into a polymer or hydrogel surface layer or layers. The applications include catheters, cannulae, needles, stents, guide wires, implant devices, filters, surgical or medical instruments, endotracheal tubes, gastroenteric feeding tubes, shunts, condoms, oxygenator and kidney membranes, gloves, pacemaker leads, wound dressings or gels, pins, plates, screws, artificial joints, and more.
InnovoSIL™-1 silver, as well as related compounds covered by this patent, has broad spectrum activity against bacterial and fungal biofilms associated with human, animal, and plant infections. InnovoSIL™-1 silver also effective against viruses and spores, and provides a potential solution to the growing challenges associated with antibiotic resistance, due to multiple unique mechanisms of action.
The issue of this patent allows Innovotech to licence these applications of antimicrobial silvers to industry partners in Europe interested in enhancing the antiplanktonic, antiviral, anti-adherence, or antibiofilm properties of their products.
About Innovotech Inc.:
Innovotech is a Canadian biotechnology company owning proprietary intellectual property, conducting contract research, and owning and providing proprietary devices for testing in multiple applications in microbiology, and can be found online at www.innovotech.ca.
Craig Milne, CEO Innovotech Inc.
+1-604-239-1819 craig.milne@innovotech.ca
This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management’s assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward- looking statements, except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
###
Copyright (c) 2025 TheNewswire - All rights reserved.